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a  b  s  t  r  a  c  t
Post-licensure  real world  evaluation  of vaccine  implementation  is important  for establishing  evidence  of
vaccine effectiveness  (VE)  and  programme  impact,  including  indirect  effects.  Large  cohort  studies  offer
an important  epidemiological  approach  for evaluating  VE,  but  have  inherent  methodological  challenges.
Since March  2012,  we  have  conducted  an  open  prospective  cohort  study  in  two  sites  in  rural
Malawi to evaluate  the  post-introduction  effectiveness  of  13-valent  pneumococcal  conjugate  vaccine
(PCV13)  against  all-cause  post-neonatal  infant  mortality  and  monovalent  rotavirus  vaccine  (RV1)  against
diarrhoea-related  post-neonatal  infant  mortality.  Our  study  sites  cover  a population  of 500,000,  with  a
baseline  post-neonatal  infant  mortality  of  25 per  1000  live  births.
We conducted  a methodological  review  of  cohort  studies  for vaccine  effectiveness  in  a  developing
country  setting,  applied  to  our  study  context.  Based  on  published  literature,  we  outline  key  consider-
ations  when  deﬁning  the  denominator  (study  population),  exposure  (vaccination  status)  and  outcome
ascertainment  (mortality  and  cause  of  death)  of such  studies.  We  assess  various  deﬁnitions  in these  three
domains,  in terms  of their  impact  on  power,  effect  size  and  potential  biases  and  their  direction,  using  our
cohort  study  for  illustration.  Based  on  this  iterative  process,  we  discuss  the pros  and  cons  of  our  ﬁnal  per-
protocol  analysis  plan.  Since  no  single  set  of  deﬁnitions  or  analytical  approach  accounts  for  all  possible
biases,  we  propose  sensitivity  analyses  to interrogate  our  assumptions  and  methodological  decisions.
In the  poorest  regions  of  the  world  where  routine  vital  birth  and  death  surveillance  are  frequently
unavailable  and  the  burden  of  disease  and death  is  greatest  We  conclude  that  provided  the  balance
between  deﬁnitions  and their  overall  assumed  impact  on estimated  VE  are  acknowledged,  such  large
scale  real-world  cohort  studies  can  provide  crucial  information  to policymakers  by  providing  robust  and
compelling  evidence  of  total  beneﬁts  of  newly  introduced  vaccines  on reducing  child mortality.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
The 13-valent pneumococcal conjugate vaccine (PCV13) and
monovalent rotavirus vaccine (RV1) were introduced to the routine
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infant vaccine schedule in Malawi in November 2011 and October
2012, respectively. Evidence of their effectiveness and population
impact on mortality in sub-Saharan Africa is needed, particularly
where HIV, malaria and malnutrition are prevalent. To date several
modelling studies have projected their impact in this setting, but
observational data on their empirically observed mortality impact,
which exist elsewhere, are lacking for sub-Saharan Africa [1–7].
Pre-licensure vaccine efﬁcacy is determined through placebo-
controlled double-blind randomized trials [8]. Post-licensure
studies are needed to determine vaccine effectiveness (VE) and
http://dx.doi.org/10.1016/j.vaccine.2015.07.062
0264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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population impact, including indirect effects (herd immunity and
changes in transmission dynamics at the population level) in the
‘real world’ setting. Effectiveness is often assumed to be lower than
efﬁcacy, since cold chain implementation and stock administration
are frequently suboptimal compared with strict trial conditions [9].
Measures of effectiveness are by nature observational and therefore
vulnerable to confounding and bias, namely being unable to fully
account for the individual decision to seek vaccination [10]. How-
ever, they may  provide a more generalizable result, and because
of size and exclusions, it is difﬁcult for licensure trials to include
an assessment of herd protection (unless randomized by cluster), a
key beneﬁt of many infant vaccines. Therefore, post-licensure effec-
tiveness evaluations are crucial for policy makers to assess vaccine
roll-out, highlight issues in programme implementation and deter-
mine total impact of direct and indirect effects at population level
[8,11].
Several observational methods exist for evaluating VE: serolog-
ical (using correlates of protection), ecological (population-level
surveillance, including analysis of electronic medical records),
cohort and case-control studies [8,12–17]. Each method has biases,
advantages and disadvantages in practice, and variable utility in
assessing potential non-speciﬁc vaccine beneﬁts or risks. Each
method also addresses slightly different questions about vaccine
effectiveness and the preferred design may  be context dependent;
for example, a case-control design where the disease is extremely
rare; or a cohort when investigating multiple outcomes for one
exposure. Using a carefully selected and complementary combi-
nation of observational methods affords a more comprehensive
understanding of vaccine impact, effectiveness and changing epi-
demiology of the target disease.
Cohort studies are resource intensive, requiring large sample
sizes if events (such as death) are uncommon or if absolute effect
sizes are small. As under-5 mortality rates are declining globally
[18], cohorts with mortality end-points will become increasingly
challenging. However, they avoid biases arising from selecting
appropriate controls and censoring by survivorship to which other
observational methods for estimating VE are more susceptible [19].
Three deﬁnitions are key to the design of a cohort study: the denom-
inator (deﬁning the study population), exposure ascertainment
(with respect to vaccination status) and outcome ascertainment
(mortality and cause of death) [20]. With these key parameters,
the standard approach to analysis would be a comparison of the
hazard of death or survival by vaccination status adjusted for key
confounders.
In this paper, we aim to discuss key methodological challenges
inherent to cohort designs focusing speciﬁcally on these three
domains and apply them to our study setting to clearly illustrate
practical considerations in establishing an a priori ‘per-protocol’
and sensitivity analysis plan. These analyses aim to give VE esti-
mates, acknowledging that in complex ﬁeld environments with
unmeasured confounding (such as bias in the decision to receive
vaccines or not), causality is difﬁcult to assign.
2. Methods
We  conducted a methodological review of cohort study design
for evaluating vaccine effectiveness in a developing country setting.
We searched Web  of Science and PubMed using the follow-
ing terms: method* AND/OR cohort, AND vaccine effectiveness
AND/OR survival analysis, and included secondary references and
highly-cited papers in the ﬁeld. Our subsequent discussion focuses
on the key challenges and considerations highlighted in the litera-
ture and use our ﬁeld setting to illustrate key considerations. Based
on this iterative process, we develop and present our primary and
sensitivity analysis plan.
Fig. 1. Schematic of study recruitment, follow up and deﬁnitions.
3. Cohort recruitment
3.1. Setting
A prospective cohort study is ongoing at two sites in Malawi:
Mchinji district in the central region, and the Karonga demographic
surveillance site (DSS) in northern Malawi [21,22]. Since 1 March
2012, we  have conducted an open prospective cohort study in Mch-
inji district, which has a population of 465,000. The DSS site in
Karonga has been running since 2002, covering a population of
35,000. Both sites are rural and the main occupation is subsistence
farming [23]. Around 20% of the population is aged under 5 years
and crude birth rate is approximately 40/1000 person years. Under-
5 mortality has declined by 18 deaths/1000 live births over a 5 year
period to a rate of 71/1000 in 2013 [24], with much of this effect
seen in post-neonatal infants. The primary research questions for
this cohort study are:
- What is the effectiveness of three doses of PCV13 against all-cause
mortality in infants?
- What is the effectiveness of two doses of RV1 against diarrhoea-
speciﬁc mortality in infants?
This study is being conducted alongside case-control studies
with a range of morbidity and laboratory conﬁrmed endpoints, to
provide comprehensive data on vaccine effectiveness and impact
in different population settings in Malawi [21].
3.2. Data collection
The DSS methods for Karonga have been published in detail
previously [22]. The Mchinji surveillance site uses similar, but less
resource-intensive methods, to the Karonga site [21]. Brieﬂy, both
systems are based on networks of volunteer village-level key infor-
mants who  report monthly on births and deaths (Fig. 1). Selecting
appropriate key informants was done with extensive community
engagement to ensure they were acceptable to the community
since without this support accurate reporting of events would be
unlikely. In Mchinji infants are followed up by ﬁeld enumera-
tors with a home visit at 4 months and 1 year of age to capture
vaccine status and conﬁrm survival. At these visits, a one-page
questionnaire is administered, collecting information on infant and
mother survival, vaccine status (from documented health record or
parental recall when documentation is unavailable), maternal edu-
cation, household composition and assets. The large population size
and human resource constraints limited the length of the question-
naire in the Mchinji setting. In the Karonga DSS, a rolling population
demographic census visits all households in the entire population
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Table 1
Summary of advantages and disadvantages of different target populations in a cohort study of vaccine effectiveness, using PCV13 as an example.
Age of inclusion Target group Advantages Disadvantages Direction of Bias Comment
4–52 weeks Post-neonatal infants High recruitment of
deceased infants
Includes vaccine
ineligible infants
Overestimated VE Includes infants who have not had
the opportunity to be vaccinated
(non-outstanding), therefore
leading to higher vaccine
effectivenessa
6–52 weeks Any dose age-eligible
infants
Relatively high
recruitment of
deceased infants
High proportion of
unvaccinated infants
Overestimated VE
14–52  weeks Fully vaccinated
infants:
age-eligible for ﬁnal
dose
Relatively high
recruitment of
deceased infants
Low vaccine coverage
and protection
Unclear direction of
bias
May  decrease VE as vaccinated but
unprotected infants are considered
vaccinated. Or may increase VE as
untimely vaccination leads to more
unvaccinated infants being
included
16–52  weeks within 2 weeks of
recommended week as
a  strict cut-off
Per guidelines
deﬁnition of
vaccination
Low vaccine coverage Unclear direction of
bias
18–52  weeks within the
recommended month
as a moderate cut-off
Moderately high
vaccine coverage
Low recruitment of
deceased infants
Inconclusive VE Using later cut-offs will decrease
recruitment of deceased infants,
reducing the power
20–52  weeks within 6 weeks of the
recommended month
as a moderate cut-off
Moderately high
vaccine coverage
Low recruitment of
deceased infants
Inconclusive VE
26–52  weeks by 6 months of age as a
liberal cut-off
High vaccine coverage Low recruitment of
deceased infants
Inconclusive VE
PCV13: 13 valent pneumococcal conjugate vaccine; VE: vaccine effectiveness.
a In this scenario, infants who were not age-eligible for all doses but died before they had the opportunity to receive all doses would still be included in the analysis as
either  unvaccinated or partially vaccinated, increasing the apparent vaccine effectiveness.
over the course of a year, survivorship and vaccine status are con-
ﬁrmed and extensive socio-economic questionnaires completed.
In both sites, households with infant deaths are visited and a ver-
bal autopsy (VA) questionnaire administered by senior research
ofﬁcers. Identical socio-economic and vaccine status questions are
asked for surviving and deceased infants. The inclusion of two study
sites, in addition to increasing sample size, allows one to act as an
independent quality check on the other.
3.3. Sample size
For PCV13, we calculated the sample size based on the base-
line assumption of a post-neonatal infant mortality of 25/1000 live
births (reported by the Karonga DSS for 2011/2012), three-dose
vaccine coverage of 75% and 12% loss to follow-up. Assuming vac-
cine can only lower and not increase mortality, we  used a one-sided
log-rank test to calculate that we require 34,848 infants surviv-
ing to 1 year and 729 deaths amongst post-neonatal infants (aged
>28 days) to have 80% power to detect PCV13 vaccine effective-
ness of ≥20% against all-cause mortality. Pneumonia, meningitis
and sepsis account for 40% of deaths in post-neonatal infants, there-
fore ≥20% effectiveness was chosen as a modest estimate of effect
size.
For RV1, our pre-RV1 introduction surveillance observed post-
neonatal infant diarrhoea-related mortality of 6/1000 live births,
and at 75% two-dose coverage and 12% loss to follow-up we require
43,668 infants and 210 diarrhoea deaths for 80% power to detect
RV1 vaccine effectiveness of 36% against diarrhoea-related deaths.
As we accrue more accurate information on cause-speciﬁc mortal-
ity and vaccine coverage, our targets may  need revision. To date
(May 2015), we have recruited 50,000 PCV13 eligible infants and
35,000 infants eligible for RV1.
4. Denominator
When deﬁning the cohort sampling frame (”target population”),
design decisions need to be made in terms of the age-eligibility and
catchment population. Several age-eligibility options are possible,
each with advantages and disadvantages with any cohort deﬁni-
tion requiring a trade-off between power and estimated effect.
Delayed timeliness in vaccine uptake means that inclusion from a
younger age increases the number of partially vaccinated deceased
infants, since they die before having the chance to receive all
doses; this may  overestimate VE as there are more deaths are in
unvaccinated infants. However, using more liberal time cut-offs to
allow for higher vaccine coverage would result in lower power (i.e.
fewer recruited deaths) and misses a critical time period for deaths.
We  opted to include infants surviving to 14 weeks for the PCV13
analysis and 10 weeks for the RV1 analysis, following them to sur-
vival at 1 year, death or migration (censoring) before 52 weeks
(Table 1). This deﬁnition maximizes cohort size, excluding only
vaccine-age-ineligible infants. We  will conduct sensitivity analyses
using 6-week (earliest age-eligibility for vaccination) and 6-month
(complete vaccination, allowing for poor timeliness) survival inclu-
sion cut-offs, and 16 and 12 weeks for PCV13 and RV1, respectively
(allowing for immunogenicity of the ﬁnal dose).
We  deﬁned the eligible catchment population as all infants ‘born
to an established household within the geographical region under
surveillance’ (i.e. Mchinji District and the Karonga DSS). An ‘estab-
lished household’ is deﬁned as one which has been reported by
village informants to have been present for at least 2 months at the
time of the birth event. This seemingly straightforward demarca-
tion is in reality more complex. For example, Mchinji district has
two international borders, numerous commercial farming estates
and neighbours the capital city district of Lilongwe which makes
migration, resulting from seasonal harvesting and urbanization,
challenging to monitor. Intricate situations (e.g. a complicated
delivery being sent to a tertiary referral centre outside the district)
may  be misrepresented under this system, but such events are rare
and unlikely to alter VE estimate substantially.
5. Exposure (vaccine status)
The exposure of interest is vaccination. Vaccination status can
be ascertained from several sources, including care-giver report
and documented health record, and the choice of source requires a
trade-off between potential bias and power. Two  key assumptions
in the analysis of observational effectiveness studies are that there
are no unmeasured systematic differences between the exposed
and unexposed and that there is no differential exposure ascertain-
ment by outcome [12]. These assumptions are likely to be violated,
as outlined below.
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5.1. Unmeasured differences between exposure groups
Vaccinated infants may  differ in other health and social meas-
ures from unvaccinated infants. In our setting, households with
lower incomes are more likely to have limited access to clean
water and sanitation and by implication higher propensity to
disease. When compounded by fewer available funds to seek
care (and therefore vaccination, as has been shown in Karonga
and elsewhere) [25–28] could result in higher mortality. Notably,
limited care seeking is also a reason why community household
surveillance is important, since such cases would be missed by
healthcare-based surveillance. With the limited socio-economic
information, we collect adequately accounting for the intricacies of
the relationship between socio-economic factors, health status and
health seeking behaviors is difﬁcult. For these same reasons, knowl-
edge of the birth and determining the vaccine status of infants
who remain unvaccinated may  be more challenging than ascer-
taining those who are subsequently vaccinated. Failure to identify
unvaccinated infants would overestimate vaccine coverage among
surviving infants resulting is a strongly biased increase in apparent
vaccine effectiveness.
5.2. Exposure ascertainment by outcome
Many developing countries have three potential sources for
ascertaining vaccine exposure: health passports, vaccine clinic reg-
isters and parental recall. In Malawi, children are issued a free
‘health passport’ at their ﬁrst encounter with the healthcare sys-
tem, in which vaccinations are recorded. All clinics that distribute
vaccines are required to document delivered antigens in gov-
ernment implemented ‘Under-1 registers’, including information
on each child’s name, date of birth and village. At ﬁrst vaccina-
tion, a non-unique sequential identiﬁer is transcribed onto the
health passport and is recorded at subsequent visits; in practice
linkage across visits is poor and linkage between facilities impos-
sible. The availability of health passports is associated with both
exposure (e.g. infants with no health passport are less likely to
have had any contact with the health system and therefore vac-
cinations) and outcome as the health passport is often buried
with deceased infants. This violates the assumption that exposure
ascertainment will not differ between deceased and surviving chil-
dren.
Although relying on documented evidence of vaccination to
determine exposure has a high positive predictive value (PPV)
for true vaccination status, it may  have poor negative predic-
tive value (NPV). Missing documentation of vaccine receipt in
surviving children (misclassiﬁcation bias), would result in appar-
ent decreased vaccine effectiveness as those truly vaccinated are
recorded as unvaccinated. In deceased infants, misclassiﬁcation
as non-exposed in those vaccinated would bias toward apparent
increased vaccine effectiveness [8]. As a quality control activ-
ity, we collect data on vaccine discrepancy between care-giver
reports and health passports immediately following vaccination.
Our data show 4% misclassiﬁcation of vaccines, with 2% undoc-
umented and 2% documented when not given, using care-giver
report as the reference standard. Since the misclassiﬁcation is ran-
domly bi-directional, poor reporting is unlikely to introduce bias
when documentation is available.
Parental recall is generally considered less reliable than doc-
umented evidence, as care-givers may  over-report vaccination to
meet expectations of health researchers or under-report if poorly
recalled or parents hope their child will receive beneﬁt of another
dose. Evidence for the direction of such bias is limited; though a
study from Kenya found parental recall underestimated vaccine
coverage compared with documented status [29]. Classifying chil-
dren according to parental report in the absence of documentation
mitigates the biases of relying solely on documented evidence,
which is less frequently available for deceased infants [30], but on
the other hand may  reduce the NPV. We  will use combined data
from the three sources to classify exposure ascertainment, apply-
ing a data reliability hierarchy to achieve the best balance between
PPV and NPV (see Supplementary Material 1).
5.3. Multiple doses
Vaccination status can be deﬁned as:Unvaccinated–received no
doses; fully vaccinated–received all scheduled doses; partially vac-
cinated.
a. Non-outstanding: received at least one scheduled dose and not
yet age-eligible for more.
b. Outstanding: received at least one scheduled dose, but age-
eligible for further doses.
Including partially vaccinated infants into the vaccinated group
could underestimate effectiveness if immune protection is partial.
Including such infants in the unvaccinated group may  result in chil-
dren with partial protection being considered unvaccinated, again
lowering estimates of vaccine effectiveness [8]. We  deﬁne exposure
based on doses received keeping partially vaccinated infants in the
analysis as a discrete category; however our primary analysis will
only include outstanding partially vaccinated infants.
Not distinguishing between outstanding and non-outstanding
partially vaccinated infants could introduce bias in complex ways.
Outstanding children are older and their delayed vaccination may
be associated with other risk factors for poor outcome (such as
poor health seeking behaviors); contrarily, an older living cohort
introduces a survivor bias. By deﬁning our cohort as infants sur-
viving to age-eligibility for the ﬁnal dose, we will not be including
non-outstanding partially vaccinated infants. Sensitivity analyses
using older and younger age cut-offs for inclusion will allow us to
investigate further the effect of partially vaccinated infants.
5.4. Deﬁning timeliness
Published timeliness deﬁnitions vary from strict (vaccination up
to 14 days after recommendation), to lenient (receipt of vaccine up
to 2 months delayed) [20,31–34]. Delayed vaccination is common
[35,36]; in our data only 10% of infants received all recommended
vaccines (BCG, four doses Polio, three doses Pentavalent and PCV13
and two doses RV1) within a fortnight of the schedule. Using a strict
deﬁnition of timeliness would impact study recruitment (Fig. 2)
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Fig. 2. Vaccine timeliness and age at death in post-neonatal infants–example of
cohort deﬁnition impacts on outcome and exposure.
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Box 1: Definition of vaccine timeliness.
We will use the following deﬁnition for deﬁning timely vaccine
receipt for PCV13 (3 doses) and RV1 (2 doses) [44]:
- Dose 1 (6 weeks) received between 4 weeks and 2 months.
- Dose 2 (10 weeks) received between 8 weeks and 4 months.
- Dose 3 (14 weeks) received between 12 weeks and 6 months.
We  will also examine actual timeliness as a continuous covari-
ate in sensitivity analysis
and may  introduce a bias as the low percentage of children who
receive their vaccines according to the strict schedule may  dif-
fer from the general population. On the other hand, including
infants with a long delay may  bias toward lower effectiveness.
The timeliness deﬁnition is a trade-off between power and effect,
strict deﬁnitions reducing power and lenient deﬁnitions reducing
detectable effect. In the primary analysis, we will include timeliness
of vaccine receipt as a covariate in the model, using the deﬁnition
in Box 1 [35].
6. Outcome
Two key issues relating to outcome are ascertainment and deﬁ-
nition, especially important for cause-speciﬁc mortality. Our study
outcomes for PCV13 and RV1, respectively, are all-cause mortal-
ity in infants aged 14−52 weeks and diarrhoea-related mortality in
infants 10−52 weeks.
6.1. Outcome ascertainment
To minimize differential censoring and misclassiﬁcation, effort
to ascertain outcomes should be equal in both outcome groups.
Misclassiﬁcation of deaths can occur for several reasons: inaccurate
age at death, misunderstanding of death deﬁnitions, and unreliable
reporting (e.g. relying on hearsay). Cultural barriers exist to openly
discussing death in Malawi (especially among neonates, while in
other cultures there may  be a gender bias), leading to misclas-
siﬁcation in reporting. Since death is uncommon more intensive
resources are required for ascertaining and verifying death than
survival. Under-ascertainment of deaths reduces both power and
apparent effectiveness, as does misclassifying survivors as deaths.
We conduct VA household visits on all under-ﬁve deaths, including
stillbirths, to mitigate misclassiﬁcation bias.
6.2. Cause-speciﬁc deﬁnitions
Like many developing countries [37], Malawi has no vital regis-
tration or death certiﬁcation system outside of the hospital setting,
therefore we use the WHO  2012 VA tool to collect data on signs
and symptoms preceding death [38]. Interpretation of such data is
the subject of vigorous debate [39]. Three options exist for analy-
sis of verbal autopsies based on the WHO  VA questions: physician
review, custom-deﬁned algorithm or standardized models such as
InterVA (www.interva.net) or InSilicoVA (arXiv:1411.3042). Physi-
cian review is resource intensive and has poor standardization,
while automated methods are highly repeatable [39–42]. In the
absence of a gold-standard, validity of cause-speciﬁc mortality
attribution of any method is unknown.
Inherently non-speciﬁc, the all-cause mortality outcome for
PCV13 lowers effect size, and our sample size calculation assumes
a modest 20% reduction in deaths. Since there may  be other
drivers for reductions in infant mortality (e.g. improved nutrition
status), the analysis would be confounded if these non-vaccine
reductions are directly associated with individual vaccine sta-
tus as well as mortality. However, we chose all-cause mortality
due to its important policy implications and because syndromes
commonly caused by Streptococcus pneumoniae (sepsis/meningitis,
pneumonia) may be clinically non-speciﬁc and caused by other
pathogens, leading to a more challenging outcome to capture accu-
rately or consistently. We  will conduct a sensitivity analysis for
PCV13 against sepsis/meningitis or pneumonia deaths as deﬁned
by standardized models, and anticipate VE will be higher for these
outcomes.
Compared with physician diagnosed diarrhoea-related mor-
tality, study-speciﬁc algorithms have high sensitivity but poor
speciﬁcity [43,44]. The latter may  lower apparent VE. This bias
arises from misclassifying non-diarrhoeal deaths as diarrhoeal or
having a lower prevalence of rotavirus amongst selected deaths
(e.g. during a cholera outbreak). Although false positives lower
apparent effectiveness, with prevalent infections like rotavirus, the
false positivity rate is lowered and the impact of the bias reduced
[30]. Standardized computer models have shown variable perfor-
mance when compared with physician review (likely a reﬂection
of ﬂaws in both techniques) [39–42]. We  have decided to use a
study-speciﬁc algorithm for diarrhoea-related mortality, and will
conduct sensitivity analyses with standardized models. The all-
cause mortality endpoint was  abandoned for RV1 since PCV13
had been introduced in the previous year, further lowering post-
neonatal infant mortality and resulting in unachievable power for
that endpoint.
7. Primary analysis of vaccine effectiveness
To calculate the vaccine effectiveness of PCV13 and RV1, we  will
use Cox proportional hazards modelling of survival to 1 year [45].
Other reasonable analytical approaches (e.g. Mantel−Haenszel
estimators, log−binomial regression, robust Poisson or negative
binomial regression [46–48]) do not account for differential cen-
soring. Cox modelling has two key assumptions: that censoring is
unrelated to the outcome and that the hazards are proportional
over time. For both assumptions, violations may occur in practice.
For example, itinerant agricultural laborers who  leave the dis-
trict for economic reasons may  have a lower socio-economic status,
which drives them to migrate, or harvesters who  temporarily reside
deep in the ﬁelds rather than at home may  have lower likeli-
hood of vaccination and independently higher mortality [26,49].
Therefore, if such families have higher infant mortality this vio-
lates the assumption that censoring is unrelated to outcome. The
assumption of proportionality may  also be violated as mortality
risk (outcome) is generally age-associated, as is vaccination (expo-
sure). Mortality in infants decreases with age while the likelihood of
being vaccinated increases with each month survived, so there may
be non-proportionality in outcomes between exposure groups over
time. Methods for testing proportionality (e.g. Schöenfeld residuals,
[50]) and mitigating its violations exist [51,52]. If we  ﬁnd the pro-
portionality assumption violated, we  will allow for time-varying
covariates [53].
7.1. Confounders and risk factors
Since both vaccine receipt and outcome may  be associated with
classical confounding, measuring and adjusting for these is criti-
cal. In a Swedish study, unadjusted inﬂuenza VE was 50% while
adjusted for confounders was 14% [54]; in our context, the magni-
tude and direction of bias are difﬁcult to predict. We will include
the following covariates in our primary analysis: socio-economic
status; other vaccine receipt, timeliness and distance to nearest
vaccination centre; mother’s survival and health centre catchment
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(as a ﬁxed variable). It is improbable that all confounders can
be accounted for and differential ascertainment of confounders
by exposure or outcome status is likely. For example, we  collect
mid-upper arm circumference (MUAC), a proxy measure of nutri-
tional status in children and a good predictor of mortality [55];
collecting MUAC for surviving children is done at follow-up, but this
is not possible for deceased children. In sensitivity analysis, we will
investigate unmeasured confounding using a method described by
Groenwold et al. [56], which simulates unmeasured confounders
based on substantive knowledge of its association with the outcome
and exposure.
8. Sensitivity analyses
The primary analysis of assessing individual vaccine status and
survival adjusted for confounders and risk factors does not provide
information on vaccine impact and is unlikely to account for all
confounders or drivers of individual decisions in vaccine uptake.
Therefore, the use of sensitivity analyses is essential for exploring
indirect effects, the role of unmeasured confounders and con-
ﬁrming the ﬁndings of the primary analysis to provide a more
complete picture of vaccine effectiveness.
8.1. Cluster-level analysis
Cluster-level analysis, either grouping by geographical region
or by time-periods, addresses programme impact [12]. We  will
regress mortality rates against vaccine coverage at a geographical
cluster level adjusting for socio-economic measures. In choosing
the cluster deﬁnition (e.g. health centre catchment, community
health worker catchment, village), we aim to maximize cluster
number while maintaining adequate cluster size and inter-cluster
heterogeneity. We  will also investigate random-effects models that
incorporate both individual and cluster-level covariates, which
allow examination of cluster effects on individual mortality hazard.
8.2. Competing risks
A key consideration in carrying out survival analysis for cause-
speciﬁc deaths is the issue of ‘competing risks’. A child dying of
pneumonia cannot then die again of diarrhoea, and so is cen-
sored. Given the relatively high infant mortality rate in Malawi,
such competing risks are an issue in the analysis of RV1 against
diarrhoea-speciﬁc mortality endpoint. Competing risks regression
will be used to investigate this, and may  help explore synergistic
effects of both vaccines [57].
8.3. Quasi-experimental approaches
Quasi-experimental approaches are used to evaluate causal
inference from observational data, in an attempt to account for
the lack of randomization in treatment assignment and there-
fore potential missed confounders (resulting in endogeneity). Two
approaches which may  be appropriate for vaccine effectiveness
using cohort data are instrumental variables and propensity score
matching. Using instrumental variables, a method widely used
in econometrics, vaccine status would be replaced with a substi-
tute exposure variable which is independent of the unmeasured
confounder, thus avoiding endogeneity [58,59]. As socio-economic
status may  differ by exposure [26] and by outcome, it can give rise to
a ‘self-selection bias’ whereby poor infants are both unvaccinated
and die as a result of poverty, increasing apparent VE even after
adjustment [49]. Using an instrumental variable could mitigate this
bias and address any issues in missing exposure status, by select-
ing a variable associated with vaccination status but independent
of socio-economic status. The challenge is selecting an appropriate
instrumental variable. One possibility is vaccine stock availabil-
ity at local clinic level. However, this too may be associated with
socio-economic status of the catchment area, with clinics closer to
tarmac roads both more likely to have regular supplies and more
trade leading to higher socio-economic status of the surrounding
population. An obvious choice for an independent instrumental
variable is lacking in our situation, precluding the use of this
method.
Propensity score matching is a method which accounts for the
probability of receiving a treatment or intervention (i.e. vaccina-
tion) based on covariates to adjust the effectiveness model. This
method has been used previously in the analysis of observational
vaccine effectiveness studies [60,61], and could provide insight into
our assumptions about residual unaccounted confounding.
9. Conclusion
The evaluation of vaccine effectiveness against mortality using
cohort studies is complex and with globally declining mortal-
ity is becoming increasingly challenging as larger cohorts that
are subject to more confounding are required. It is imperative to
ensure that estimates of vaccine effectiveness are as valid and
accurate as possible despite the biases inherent in large-scale,
real-world observational studies. The complexities we have iden-
tiﬁed, such as differential vaccine ascertainment and lack of gold
standard cause of death information, are likely to challenge vac-
cine evaluations in other low-resource settings and our approach
to deﬁning the primary analysis is generalizable to similar study
designs.
While no single set of deﬁnitions or analytical approach can
address all possible biases and confounding, the careful a priori
consideration of denominator, exposure and outcome deﬁnitions
and of the analytical approaches can achieve a balanced ‘per-
protocol’ primary analysis (Box 2), which errs toward conservative
estimation of vaccine effectiveness. Sensitivity analyses are cru-
cial to interrogate assumptions and methodological decisions, and
to explore more subtle relationships between mortality, vaccine
exposure and inherent confounders. Only large-scale cohort stud-
ies can generate crucial evidence of total community mortality
reduction from vaccines in resource poor settings, which lack rou-
tine vital registration and where mortality burden is greatest. Such
studies provide essential information to policymakers by provid-
ing robust and compelling evidence of total beneﬁts of vaccines on
reducing mortality.
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